# Ferumoxytol-enhanced Magnetic Resonance Imaging

> **NCT02954510** · PHASE3 · UNKNOWN · sponsor: **Brigham and Women's Hospital** · enrollment: 185 (estimated)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** ferumoxytol

## Key facts

- **NCT ID:** NCT02954510
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-02-01
- **Primary completion:** 2023-11-01
- **Final completion:** 2024-02-27
- **Target enrollment:** 185 (ESTIMATED)
- **Last updated:** 2023-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02954510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02954510, "Ferumoxytol-enhanced Magnetic Resonance Imaging". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02954510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*